UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
Status:
Active, not recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
With this study - Total Therapy IIIB - researchers are extending the findings of Total
Therapy III based what they have learned from the first two studies (Total Therapy I and II),
with new research strategies designed to explore why chromosome abnormalities found in
persons with multiple myeloma affect the outcome of drug therapy used in this disease."